Oramed Pharmaceuticals Set to Join Russell 2000 and 3000 Indexes

Key Facts

In a move highlighting the evolving landscape of small-cap biotech firms, Oramed Pharmaceuticals announced its upcoming inclusion in the Russell 2000 and Russell 3000 Indexes. This addition is part of the 2026 annual index reconstitution conducted by FTSE Russell. The inclusion is determined by market capitalization rankings and signifies a milestone in the company's corporate growth.

Inclusion in the Russell 2000 typically triggers mandatory buying from passive investment vehicles, such as the iShares Russell 2000 ETF (IWM). Per market data, such index adjustments are critical for small-cap liquidity, as the Russell 3000 serves as a benchmark for approximately 98% of the investable U.S. equity market. This transition often leads to increased institutional ownership and broader analyst coverage.

Shares of ORMP stood at $3.77 (close June 16, 2026), having reached a daily high of $3.91. Investors should watch for the effective date on June 29, 2026, when index-tracking funds are expected to finalize their positions. Additionally, the broader market sentiment may be influenced by the Michigan Consumer Sentiment data scheduled for release on June 12, according to the economic calendar.